Pneumococcal vaccine conjugate 13-valent - Beijing Minhai Biotechnology

Drug Profile

Pneumococcal vaccine conjugate 13-valent - Beijing Minhai Biotechnology

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator Beijing Minhai Biotechnology
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pneumococcal infections

Most Recent Events

  • 01 Jun 2016 Phase-III clinical trials in Pneumococcal infections (Prevention) in China (IM) (NCT02494999)
  • 22 Jul 2015 Jiangsu Province Center for Disease Control and Prevention and Beijing Minhai Biotechnology plan a phase III trial for Pneumococcal infections (Prevention, In infants) in China (NCT02494999)
  • 31 Dec 2014 Phase-I clinical trials in Pneumococcal infections (Prevention) in China (IM) before December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top